CA3148326A1 — Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
Assigned to Intra Cellular Therapies Inc · Expires 2015-06-11 · 11y expired
What this patent protects
The disclosure provides the use of substituted heterocycle fused gamma-carboline compounds of Formula I as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of substituted h…
USPTO Abstract
The disclosure provides the use of substituted heterocycle fused gamma-carboline compounds of Formula I as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of substituted heterocycle fused gamma-carboline compounds of Formula I and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.